KRAS and neoplasm: In vivo evaluations of RMC-6236 resulted in significant and durable tumor regression across multiple tumor types, particularly in NSCLC and pancreatic adenocarcinomas harboring KRAS glycine-12 substitutions (KRAS G12X) [43].